title: Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study.
abstract: OBJECTIVE
  To investigate the somatostatin analog lanreotide as symptomatic treatment for inoperable bowel obstruction due to peritoneal carcinomatosis.
  
  
  METHODS
  In all, 80 patients with peritoneal carcinomatosis, inoperable malignant digestive obstruction, and two or more vomiting episodes per day or nasogastric tube (NGT) who were previously treated with intravenous corticosteroids and proton pump inhibitors were randomly assigned to one 30-mg injection of lanreotide microparticles (n = 43) or placebo (n = 37) in a 10-day, double-blind, parallel-group phase. The primary end point was the proportion of patients responding on day 7 (one or fewer episodes of vomiting per day or no vomiting recurrence after NGT removal [for ≥ 3 consecutive days in both cases]). Vomiting frequency/NGT secretion volumes, nausea, abdominal pain, well-being, and safety were also assessed. Patients could then enter an open-label lanreotide-only phase. The study was conducted at 22 European hospitals.
  
  
  RESULTS
  More patients receiving lanreotide than placebo were responders; this difference was not statistically significant for the intent-to-treat (ITT) population on the basis of diary cards (primary analysis; 41.9% [18 of 43] v 29.7% [11 of 37], respectively; odds ratio, 1.75; 95% CI, 0.68 to 4.49; P = .24) but was statistically significant for the corresponding supportive per protocol analysis (57.7% [15 of 26] v 30.4% [seven of 23]; P < .05) and ITT analysis, on the basis of investigators' assessments (50.0% [19 of 38] v 28.6% [10 of 35]; P < .05). Improvements in well-being were significantly greater with lanreotide on days 3, 6, and 7. No significant differences were observed for other secondary end points. Only two (mild/moderate) treatment-emergent adverse events were considered related to lanreotide.
  
  
  CONCLUSIONS
  These results show that lanreotide has some efficacy and is safe in the symptomatic treatment of patients with inoperable bowel obstruction due to peritoneal carcinomatosis.
authors.affiliation: Institut Curie, Paris Cedex 05, France. pascale.mariani@curie.net
authors.forename: Pascale
authors.initials: P
authors.lastname: Mariani
authors.forename: Joëlle
authors.initials: J
authors.lastname: Blumberg
authors.forename: Alain
authors.initials: A
authors.lastname: Landau
authors.forename: Daniela
authors.initials: D
authors.lastname: Lebrun-Jezekova
authors.forename: Estelle
authors.initials: E
authors.lastname: Botton
authors.forename: Olivier
authors.initials: O
authors.lastname: Beatrix
authors.forename: Didier
authors.initials: D
authors.lastname: Mayeur
authors.forename: Robert
authors.initials: R
authors.lastname: Herve
authors.forename: Pascal
authors.initials: P
authors.lastname: Maisonobe
authors.forename: Laure
authors.initials: L
authors.lastname: Chauvenet
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007415:Intestinal Obstruction / Q000188:drug therapy* / Q000209:etiology*; D008297:Male; D010316:Particle Size; D010456:Peptides, Cyclic / Q000008:administration & dosage* / Q000009:adverse effects; D010534:Peritoneal Neoplasms / Q000150:complications* / Q000188:drug therapy*; D010919:Placebos; D013004:Somatostatin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000970:Antineoplastic Agents; D010456:Peptides, Cyclic; D010919:Placebos; C060347:lanreotide; D013004:Somatostatin